HomepagePTKFF • OTCMKTS
add
Kalbe Farma Tbk PT
Vorige slotkoers
$Â 0,075
Jaar-range
$Â 0,065 - $Â 0,11
Beurswaarde
67,97Â bln. IDR
Gem. volume
117,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
IDX
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(IDR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 8,85Â bln. | 5,77% |
Bedrijfskosten | 2,24Â bln. | 9,58% |
Netto inkomsten | 1,08Â bln. | 12,45% |
Netto winstmarge | 12,17 | 6,29% |
Winst per aandeel | 23,57 | 13,86% |
EBITDA | 1,57Â bln. | 11,60% |
Effectief belastingtarief | 22,83% | — |
Balans
Totale activa
Totale passiva
(IDR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 4,69Â bln. | 10,74% |
Totale activa | 30,58Â bln. | 5,59% |
Totale passiva | 5,22Â bln. | 7,63% |
Totaal aandelenvermogen | 25,36 bln. | — |
Uitstaande aandelen | 45,65 mld. | — |
Koers-boekwaardeverhouding | 0,00 | — |
Rendement op activa | 11,54% | — |
Rendement op kapitaal | 13,57% | — |
Kasstroom
Nettomutatie in liquide middelen
(IDR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 1,08Â bln. | 12,45% |
Operationele kasstroom | 344,56Â mld. | -71,44% |
Kasstroom uit beleggingen | -118,66Â mld. | 61,24% |
Kasstroom uit financiering | -423,13Â mld. | -791,88% |
Nettomutatie in liquide middelen | -180,46Â mld. | -121,28% |
Vrije kasstroom | -102,67Â mld. | -114,36% |
Over
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Opgericht
10 sep 1966
Website
Werknemers
12.841